Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
Key Financial Performance
Revenue Neogen delivered revenue of approximately $209 million, up 0.3% year-over-year on a core basis. The increase was driven by growth in key product lines like food quality and pathogens, though Petrifilm experienced a mid-single-digit decline due to distributor changes in Asia and normalization of buying patterns in the U.S.
Food Safety Segment Revenue Revenues were $152 million, down 4.6% compared to the prior year, including a core decline of 1.7%. Growth was seen in pathogens, allergens, bacterial and general sanitation, and sample collection, but declines occurred in indicator testing and culture media product categories. Petrifilm core revenue declined due to distributor inventory adjustments in the U.S. and a distributor change in Asia Pacific.
Animal Safety Segment Revenue Quarterly revenues were $57 million, a decline of 0.8%, with core revenue growth of 5.8%. Growth was driven by higher sales in Animal Care (biologics and wound care), Life Sciences (substrates and reagents), and biosecurity (insect control products).
Adjusted EBITDA Adjusted EBITDA was $35.5 million, representing a margin of 17%. The margin was negatively impacted by lower volume, gross margin headwinds (elevated sample collection inefficiencies and tariff impacts), and higher operating expenses.
Free Cash Flow Free cash flow in the quarter was an outflow of $13 million, an improvement of $43 million compared to the prior year. This was driven by lower CapEx and improved trade working capital efficiency, which contributed an inflow of about $30 million.
Gross Margin Gross margin was 45.4%, showing sequential improvement from the prior quarter but still impacted by elevated sample collection inefficiencies and higher tariff rates.
Adjusted Net Income and EPS Adjusted net income was $9 million, and adjusted earnings per share (EPS) was $0.04, compared to $14 million and $0.07 in the prior year. The decline was due to lower adjusted EBITDA, which offset lower interest expenses.
Debt and Cash Position Gross debt was $800 million, with 68% at a fixed rate, and total cash was $139 million. The company paid down $100 million in debt using proceeds from the divestiture of the cleaners and disinfectants business, resulting in annualized interest savings of roughly $6 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Petrifilm: Initial product testing has begun with promising early results. Production testing is expected to be completed in the next few months, with full validation and transition of individual SKUs planned for the second quarter of the next fiscal year.
Market Expansion in the U.S.: Focus on accelerating growth in the U.S. market by optimizing the portfolio for market share gains and profitability, including targeted price increases and potential addition of commercial headcount in select markets.
Cost Reduction: Global headcount reduced by approximately 10%, resulting in annualized savings of $20 million. Savings will be reinvested in commercial and R&D capabilities.
Inventory Optimization: Efforts underway to optimize inventory management through S&OP processes to reduce write-offs and streamline the supply chain.
Sample Collection Inefficiencies: Addressing inefficiencies in sample collection production to improve cash flow and reduce inventory write-offs.
Strategic Focus: No major strategic overhaul planned. Focus on disciplined prioritization, scaling effective processes, and reinvigorating innovation in core food safety and animal health categories.
Deleveraging: Efforts to drive EBITDA growth and free cash flow generation to reduce debt. $100 million debt repaid in Q1 using proceeds from divestiture.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Execution challenges: The company is facing execution challenges that are holding back its operational and financial potential. This includes inconsistencies in supply and challenges related to the 3M integration, which have impacted market share in certain product lines.
Cost structure misalignment: The company has added costs over the last few years to scale up capabilities and absorb the 3M transaction, but these costs were based on higher revenue levels that have not materialized. This has necessitated a global headcount reduction of approximately 10% and other cost-cutting measures.
Inventory inefficiencies: Elevated inventory levels have led to significant write-offs and tied up cash. The company is working to optimize its sales and operations planning (S&OP) process to address this issue.
Sample collection inefficiencies: Production inefficiencies in the sample collection product line have been a drag on cash flow and gross margins. These inefficiencies are being addressed but remain a multi-quarter challenge.
Petrifilm production transition: The transition of Petrifilm production is a critical project with potential challenges, including reliance on a primary machine builder and the need for detailed process documentation. The company is managing this closely to ensure continuity of supply.
Market share loss in Food Safety: The Food Safety segment has experienced modest core revenue growth and even declines in certain quarters, indicating a loss of market share. This is attributed to execution challenges and supply inconsistencies.
Geopolitical and trade policy impacts: Shifting supply chains in response to global trade policies have negatively impacted performance in certain regions, particularly in China and ASEAN countries.
Tariff costs: Higher tariff rates have impacted gross margins, although the company is taking pricing and resourcing actions to mitigate this.
Regulatory and compliance risks: The company operates in a highly regulated industry, and any failure to comply with food safety and animal health regulations could adversely impact its operations and reputation.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Driving top-line growth: Empowering commercial teams to target higher growth markets, particularly in the United States. Optimizing the portfolio for market share gains and profitability, including targeted price increases. Evaluating the addition of commercial headcount in select markets to capture incremental growth opportunities. Recruiting a Chief Commercial Officer to provide dedicated global commercial leadership.
Rightsizing cost base: Reducing operating expenses by approximately $20 million annually through a global headcount reduction of 10% and non-labor cost reductions. Targeted reinvestment in commercial and R&D capabilities to enhance demand generation.
Reinvigorating innovation: Strengthening the R&D pipeline in core food safety and animal health categories. Prioritizing fewer high-impact projects, investing in top talent, and enhancing innovation processes. Advancing Petrifilm production integration and addressing sample collection inefficiencies through productivity enhancements.
Deleveraging: Focusing on EBITDA growth and free cash flow generation. Optimizing the S&OP process to release excess inventory and improve cash generation. Addressing inefficiencies in the sample collection product line to reduce cash drag.
Revenue growth: Reaffirming full-year guidance for fiscal 2026. Expecting modest sequential revenue growth in Q2 compared to Q1. Anticipating revenue growth driven by enhanced commercial and innovation focus.
Cost savings: Annualized cost savings of $20 million from headcount reduction and non-labor cost reductions, with $12 million expected to benefit fiscal 2026.
Petrifilm production: Production testing expected to be completed within the next couple of months, with full validation and transfer of production during the second quarter of the next fiscal year. Ensuring continuity of supply during the transition process.
Genomics business: Process to sell the genomics business is progressing well. Guidance will be adjusted post-sale.
Free cash flow: Improved free cash flow expected through reduced CapEx and working capital efficiency. Targeting further cash generation by optimizing inventory and addressing inefficiencies in sample collection.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you talk about the time period during the interview process and what gave you confidence to take the role at Neogen?
A:Mikhael Nassif expressed that he was attracted to Neogen due to its growing market, strong portfolio, and significant opportunity to unlock shareholder value. He highlighted the dedication of employees and the need to build core processes, scale S&OP, and align functions to drive value. He acknowledged share losses in sample collection, allergens, and natural toxins due to supply challenges but noted strengths in pathogens and Petrifilm.
Q:How do you take share with unique products like Petrifilm?
A:Mikhael Nassif outlined three strategies: leveraging Neogen's broad portfolio and trusted partnership with customers, addressing underpenetrated markets like Europe for Petrifilm, and focusing on commercial excellence to target accounts and position products effectively. He emphasized the importance of execution and discipline within the commercial organization.
Q:How should we expect EBITDA margins and EBITDA to progress through the year?
A:Dave Naemura stated that EBITDA margins are expected to progress as the year advances. Improvements are anticipated from volume growth, restructuring benefits, and addressing inventory and sample collection challenges. He confirmed the need for a north of 20% margin exiting the year and promised more clarity as the year progresses.
Q:What is a reasonable timeline for investors to expect a vision and timeline for the company to play offense?
A:Mikhael Nassif indicated that while the strategic focus areas remain unchanged, specific actions like headcount reduction are being taken. He expects to outline a more detailed vision by early 2026, focusing on quick wins, cost management, and critical project delivery in the meantime.
Q:Why didn’t you raise revenue guidance despite beating revenue estimates?
A:Dave Naemura explained that there were no one-time events or pull-forwards in Animal Safety. The decision to maintain guidance was due to early-year uncertainty, particularly around sample collection volumes.
Q:Can you discuss margins and cash flow pressures and confidence in expansion opportunities?
A:Dave Naemura acknowledged challenges in inventory and sample collection but highlighted robust incremental margins and improvements in end-market exposures. He confirmed confidence in the $15 million Petrifilm duplicative cost guide and noted that cash flow improvement depends on revenue conversion and operational efficiencies.
Q:How has Neogen managed execution challenges without impacting the new product pipeline?
A:Mikhael Nassif stated that execution challenges stem from misaligned priorities and integration issues. He emphasized the need to streamline operations and enhance accountability. He also highlighted plans to reinvigorate innovation by building an externally informed strategy and focusing on high-impact opportunities.
Q:What is the core margin operating level this year, and what are the opportunities for margin recovery?
A:Dave Naemura noted that headwinds in Q1 caused a few hundred basis points of margin impact. He expects improvements in the second half due to volume growth, cost structure benefits, and operational improvements. He highlighted the $20 million annualized OpEx savings as a key factor.
Q:What are the $6 million in sample collection costs, and will they continue?
A:Dave Naemura explained that these costs are due to scrap, quality flags, and excess production costs, resulting in selling products at a loss. Improvements are expected as back orders are reduced, labor costs are lowered, and machine uptime is optimized. He anticipates positive results by Q3.
Q:How is Neogen addressing headcount reduction and turnover while stabilizing the business?
A:Mikhael Nassif emphasized the importance of aligning resources to maximize growth and continuously evaluating the organization. He acknowledged turnover challenges but highlighted the workforce's dedication and plans to realign priorities, improve processes, and upgrade roles to build a best-in-class organization.
Q:What is the status of Neogen’s portfolio assessment and potential divestitures?
A:Mikhael Nassif and Dave Naemura confirmed alignment with the current portfolio strategy, focusing on optimizing remaining product lines for growth. They acknowledged ongoing portfolio reviews but expressed satisfaction with the current portfolio after recent divestitures.
Q:How do you reconcile reduced back orders with excess spoiling inventory?
A:Dave Naemura clarified that reduced back orders pertain to sample collection, while excess inventory issues are related to shelf-life management and S&OP process inefficiencies. He emphasized ongoing efforts to improve these processes.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct timeline for achieving margin recovery and did not offer precise details on the core margin operating level for the year. Additionally, while they acknowledged challenges in inventory and sample collection, their responses lacked specific data or actionable steps to address these issues comprehensively.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
APAC inventory
APAC region
EMEA
Poland
RD
benefit
capability
care
category sale
collection product
core food
cost base
country
decline core
detail
distribution channel
generation
guide
headcount reduction
improvement balance
inefficiency
integration sample
inventory write
leader
level reinvestment
line expectation
margin improvement
point divestiture
process sale
productivity
reduction force
remainder
respect
saving
supply chain
transaction
transfer
urgency
write offs
NEOG Transcript
Neogen Corporation (NEOG) Q2 2026 Earnings Call Transcript
Positive1-8
The earnings call reveals strong financial performance with improved margins and EBITDA, alongside optimistic guidance. The Q&A section highlights effective management and strategic initiatives, such as the Petrifilm manufacturing process and commercial organization changes. Despite some conservative guidance and ongoing challenges, the overall sentiment is positive, with raised guidance and customer confidence in key product lines. Given the market cap, the stock price is likely to react positively, but not overwhelmingly so.
Neogen Corporation (NEOG) Q1 2026 Earnings Call Transcript
Unknown10-9
The earnings call summary presents a mixed picture: while there are positive aspects like the strong performance of Petrifilm and expected EBITDA margin improvement, there are concerns about supply challenges, margin pressures, and a lack of raised guidance despite revenue beats. The Q&A section reveals management's cautious stance, especially regarding early-year uncertainties and execution challenges. These factors, combined with the company's mid-sized market cap, suggest a neutral stock price movement in the short term.
Neogen Corporation (NEOG) Q4 2025 Earnings Call Transcript
Unknown7-29
The earnings call revealed declines in core revenues across segments, a significant goodwill impairment, and a lowered EBITDA. Despite some positive updates, like pathogen testing growth and reduced CapEx, the overall sentiment is negative due to the weak financial performance and market outlook. The Q&A highlighted concerns about tariffs and macroeconomic pressures, further dampening investor sentiment. With a market cap of $3.45 billion, the stock is likely to experience a negative reaction, falling within the -2% to -8% range over the next two weeks.
Neogen Corporation (NASDAQ:NEOG) Q3 2025 Earnings Call Transcript
Unknown4-10
The earnings call reveals several concerning factors: missed EPS expectations, downward revenue and EBITDA guidance, and significant macroeconomic and tariff headwinds. Despite some positive aspects like restructuring efforts and U.S. food safety growth, the lack of a share repurchase program and unclear management responses in the Q&A contribute to a negative sentiment. The company's market cap suggests a moderate reaction, leading to a predicted stock price decline of -2% to -8% over the next two weeks.
NEOG Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
